EGFR signaling has been implicated in tamoxifenresistance in preclinical models [36, 37], which could have significant implications for treatment, and lends further credence for EGFR pathway overexpression contributing to worse clinical outcomes in ER+ preM breast cancers. The gene discussed is EGFR; the disease is breast carcinoma.